Support for Gilead Drug ' s Benefit Against Multidrug-Resistant HIV Support for Gilead Drug ' s Benefit Against Multidrug-Resistant HIV

Lenacapavir produces higher levels of viral suppression after 26 weeks among patients with multidrug-resistant disease when given in addition to other antiretrovirals, according to results from the CAPELLA trial.Reuters Health Information
Source: Medscape Hiv-Aids Headlines - Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news